Drugs / GS-441524
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06274853 | Jun → Dec 2024 | COVID-19 | National Center for Advancing Translational Sciences (NCATS) | Withdrawn | No outcome recorded |
| Phase 1 | NCT04859244 | Jan → May 2021 | COVID-19 | Copycat Sciences LLC | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2021-07-22 | Lexaria Bioscience Corp. | Results Lexaria Summarizes Successful Antiviral Drug Studies and Ongoing Strategy lexariabioscience.com ↗ |
| 2021-06-15 | Lexaria Bioscience Corp. | Results Lexaria Drug Delivery Platform Enables up to Three-Fold Increase in Oral Delivery of Antiviral Drugs lexariabioscience.com ↗
Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (CSE:LXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to announce positive results from its tolerability and pharmacokinetic (“PK”) animal study VIRAL-A20-2, evaluating DehydraTECH-enabled remdesivir and ebastine. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2021-07-22 | Lexaria Bioscience Corp. | Lexaria Summarizes Successful Antiviral Drug Studies and Ongoing Strategy lexariabioscience.com ↗ |
| 2021-06-15 | Lexaria Bioscience Corp. | Lexaria Drug Delivery Platform Enables up to Three-Fold Increase in Oral Delivery of Antiviral Drugs lexariabioscience.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GS-441524 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04859244 ↗ |
| Modality | Small molecule | — CHEMBL2016757 ↗ |
| Route | Oral | “orally administered GS-441524” NCT04859244 ↗ |